Overview

Aryl hydrocarbon receptor nuclear translocator (ARNT) is a gene that encodes a protein that functions in promoting the expression of genes involved in xenobiotic metabolism. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.

ARNT is altered in 0.15% of all cancers with breast invasive ductal carcinoma, high grade ovarian serous adenocarcinoma, invasive breast carcinoma, lung adenocarcinoma, and anaplastic astrocytoma having the greatest prevalence of alterations [3].

The most common alterations in ARNT are ARNT C181S (0.39%), ARNT G174D (0.22%), ARNT K140R (0.22%), ARNT L232V (2.94%), and ARNT L548F (0.22%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.